Loading…
Employees: 985
Size JCR Pharmaceuticals (4552.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $383M, the 1209th largest of 1,379 Japan companies the cockpit tracks. Shares closed at ¥488 on 6 Nov 2026.
Performance Over six months the shares fell 10.6%, against -21.0% for the median peer and +1.8% for the Japan market (cap-weighted) — 8th highest of 20 in its peer set.
Growth Revenue grew 3.0% over the last twelve months (peer median +9.4%); the operating margin is -13.8% (peer median -6.4%).
Valuation It trades at 203.1× forward earnings.
Capital Return on invested capital runs 8.9 points below its cost of capital (5.0% WACC).
Next results Next results expected around 28 Jan 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥38.9B | ¥40.3B | ¥33.1B | ¥42.9B | ¥34.3B |
| Revenue growth | — | +22% | -23% | +25% | — |
| Gross profit | ¥27.3B | ¥30.1B | ¥22.0B | ¥31.3B | ¥25.5B |
| EBITDA | -¥3.20B | ¥2.99B | -¥3.04B | ¥10.7B | ¥6.97B |
| Net income | -¥3.40B | ¥2.18B | -¥4.46B | ¥5.51B | ¥3.77B |
| Free cash flow | n/a | -¥11.6B | -¥15.4B | ¥7.79B | -¥13.2B |
| Capital expenditure | n/a | ¥11.6B | ¥9.67B | ¥2.10B | ¥8.56B |
| Total debt | ¥63.7B | ¥54.0B | ¥38.3B | ¥23.4B | ¥22.9B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 4552.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -0.4% | -12.6% | 4th highest of 21 |
| 6-month return | -10.6% | -21.0% | 8th highest of 20 |
| Distance from 52-week high | -40.8% | -40.6% | 11th highest of 21 |
| Revenue growth (TTM) | +3.0% | +9.4% | 8th lowest of 18 |
| Operating margin | -13.8% | -6.4% | 8th lowest of 18 |
| Forward P/E | 203.1× | n/a | — |
| ROIC minus cost of capital | -8.9 pp | -8.2 pp | 8th lowest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| JCR Pharmaceuticals 4552.T | Japan | $383M | -11% | +3% | -14% | 203.1× | n/a | n/a |
| MapLight Therapeutics MPLT | United States | $385M | -75% | n/a | n/a | n/a | n/a | n/a |
| iX Biopharma 42C.SI | Singapore | $386M | +10% | -12% | -140% | n/a | n/a | n/a |
| Guizhou Yibai Pharmaceutical 600594.SS | China | $376M | -21% | -26% | -15% | n/a | 9.0% | -11.3% |
| Rezolute RZLT | United States | $375M | +21% | n/a | n/a | n/a | n/a | n/a |
| Tiansheng Pharmaceutical 002872.SZ | China | $392M | +15% | -1% | -13% | n/a | 23.2% | -15.7% |
| Heartseed 219A.T | Japan | $393M | +52% | +197% | 9% | n/a | 50.0% | +73.2% |
| SanBio 4592.T | Japan | $393M | -58% | n/a | n/a | n/a | n/a | n/a |
| Unichem Laboratories UNICHEMLAB.NS | India | $373M | +28% | +9% | 5% | n/a | n/a | n/a |
| Chongqing Hifuture Information Technology 002168.SZ | China | $372M | -23% | +2% | -6% | n/a | 16.3% | -14.0% |
| Anhui Fengyuan Pharmaceutical 000153.SZ | China | $372M | -17% | -24% | 3% | n/a | 4.2% | +3.1% |
| Avalo Therapeutics AVTX | United States | $372M | -68% | -87% | -154,844% | n/a | n/a | n/a |
| Shukra Pharmaceuticals SHUKRAPHAR.NS | India | $372M | n/a | +115% | 57% | n/a | n/a | n/a |
| Zota Health Care ZOTA.NS | India | $395M | -6% | +69% | -16% | n/a | n/a | n/a |
| Kingchem (Liaoning) Life Science 301509.SZ | China | $368M | -25% | +3% | 6% | n/a | 13.2% | +6.5% |
| Tuoxin Pharmaceutical 301089.SZ | China | $400M | -22% | +17% | -20% | n/a | n/a | n/a |
| Hinova Pharmaceuticals 688302.SS | China | $366M | -24% | +251% | -195% | n/a | n/a | n/a |
| Kwality Pharmaceuticals KPL.NS | India | $401M | +111% | +38% | 21% | n/a | n/a | n/a |
| Hyundai Bioscience 048410.KS | South Korea | $401M | -58% | +78% | -580% | n/a | n/a | n/a |
| Guangdong Lifestrong Pharmacy 301111.SZ | China | $401M | -16% | +7% | -2% | n/a | n/a | n/a |
| JW Pharmaceutical 001060.KS | South Korea | $402M | -28% | +10% | 14% | 6.2× | -16.9% | +7.2% |